Goal of 100,000 Participants Within Five Years to Help
Scientists Better Understand Genetic Variations in Patients with
Chronic Kidney Disease
WALTHAM,
Mass., April 13, 2022 /PRNewswire/ -- Fresenius
Medical Care, the world's leading provider of products and services
for people with advanced kidney disease, announced today that the
company's Global Medical Office has launched the My Reason®
campaign to promote patient enrollment in the company's
kidney-focused genomics registry which was first introduced
last year.
![(PRNewsfoto/Fresenius Medical Care North Am) (PRNewsfoto/Fresenius Medical Care North Am)](https://mma.prnewswire.com/media/655917/FMC_Logo.jpg)
With the ambitious goal of enrolling more than 100,000
participants within five years, the campaign will help build the
registry into one of the largest of its kind by making
participation a standard offering to patients in Fresenius Kidney
Care dialysis centers in the United
States. The data collected by My Reason will serve as a
critical research tool linking genomic and clinical data of chronic
kidney disease (CKD) and end stage kidney disease (ESKD)
participants, helping scientists better understand genetic
variations in patients. Over time we believe this research will
lead to more precise diagnoses and therapies that improve outcomes
by individualizing care.
"My Reason will help us build a groundbreaking registry of
people with advanced kidney disease from diverse ethnic and
cultural backgrounds," said Franklin W.
Maddux, MD, Global Chief Medical Officer of Fresenius
Medical Care. "Pulled from such a large population of patients,
when paired with existing clinical data, this data set at scale
will help scientists untangle the complex interactions that lead to
kidney injury and use genetic sequencing to better understand
pathways of injury in kidney disease."
Both patients and their family members residing in the United States are eligible to participate
in the My Reason campaign that launched at the beginning of
April.
Fresenius Medical Care provides dialysis treatments to about
350,000 patients around the globe. This renal-focused genomic
registry was opened in select Fresenius Kidney Care dialysis
centers in January 2021. As part of
its growth strategy, Fresenius Medical Care is using digital
technologies and has the capability to analyze huge amounts of data
to develop new forms of renal therapy and collaborate with
computational experts in the genetic understanding of kidney
disease.
Nephrology has been under-represented in clinical research, even
as rapid progress in gene sequencing and analysis has led to
advances in precision medicine and individualized care in oncology,
cardiology, and other medical areas. The Global Medical Office
developed the registry to help researchers unlock new genomic
insights, filling a gap in large-scale phenotypic and genotypic
data that had been identified as a critical need.
To learn more about the My Reason campaign and enroll in this
groundbreaking initiative, please visit
https://whatsyourreason.com/.
Fresenius Medical Care is the world's leading provider of
products and services for individuals with renal diseases of which
around 3.5 million patients worldwide regularly undergo dialysis
treatment. Through its network of 4,073 dialysis clinics, Fresenius
Medical Care provides dialysis treatments for 349,167 patients
around the globe. Fresenius Medical Care is also the leading
provider of dialysis products such as dialysis machines or
dialyzers. Along with the core business, the company focuses on
expanding the range of related medical services in the field of
Care Coordination. Fresenius Medical Care is listed on the
Frankfurt Stock Exchange (FME) and on the New York Stock Exchange
(FMS).
For more information visit the company's website
at www.freseniusmedicalcare.com.
Disclaimer:
This release contains forward-looking statements that are
subject to various risks and uncertainties. Actual results could
differ materially from those described in these forward-looking
statements due to various factors, including, but not limited to,
changes in business, economic and competitive conditions, legal
changes, regulatory approvals, impacts related to COVID-19, results
of clinical studies, foreign exchange rate fluctuations,
uncertainties in litigation or investigative proceedings, and the
availability of financing. These and other risks and uncertainties
are detailed in Fresenius Medical Care AG & Co. KGaA's reports
filed with the U.S. Securities and Exchange Commission. Fresenius
Medical Care AG & Co. KGaA does not undertake any
responsibility to update the forward-looking statements in this
release.
Media Contact:
Brad Puffer
Fresenius Medical Care North America
781-699-3331
Brad.Puffer@freseniusmedicalcare.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/fresenius-medical-care-launches-my-reason-campaign-to-enroll-patients-in-groundbreaking-renal-focused-genomic-registry-301524846.html
SOURCE Fresenius Medical Care Holdings, Inc.